KEY POINTS
- This systematic review and meta-analysis included 12 retrospective comparative studies involving 2,129 patients with locally advanced cervical cancer treated with definitive radiotherapy and brachytherapy. The investigators distinguished comparisons of MRI-based or image-guided adaptive brachytherapy with historical conventional or non-volumetric techniques from direct comparisons with contemporary CT-guided brachytherapy. Importantly, the experimental groups were heterogeneous and sometimes incorporated MRI-assisted CT planning rather than MRI guidance at every treatment fraction.
- Modern image-guided brachytherapy was associated with improved overall survival compared with historical conventional techniques. Across three studies comprising 427 patients, MRI-based or image-guided brachytherapy was associated with a lower mortality hazard (HR 0.50, 95% CI 0.36–0.71; I²=0%). However, these comparisons frequently spanned different treatment eras and incorporated simultaneous changes in applicator technology, target delineation, dose optimization, and supportive care.
- Disease-control outcomes also favored image-guided treatment over historical approaches. Two studies involving 188 patients yielded a pooled progression-free or disease-free survival HR of 0.31 (95% CI 0.20–0.50). In a separate analysis involving the same number of patients, image-guided treatment was associated with improved pelvic disease control (HR 0.19, 95% CI 0.09–0.42; p<0.0001). These results support the broader transition toward volumetric image-guided brachytherapy but do not isolate the contribution of MRI guidance itself.
- Direct comparison with contemporary CT-guided brachytherapy did not establish an overall survival advantage for MRI. Only two studies comprising 114 patients, including 54 treated with MRI guidance and 60 with CT guidance, contributed to this analysis. The pooled overall survival estimate was HR 0.59 (95% CI 0.27–1.29; I²=0%), with confidence intervals compatible with substantial benefit or little difference. The absence of statistical significance does not demonstrate equivalence between the two approaches.
- Progression-related outcomes similarly failed to establish superiority over modern CT guidance. Two studies involving 114 patients yielded a pooled HR of 0.81 (95% CI 0.43–1.51). However, one study reported progression-free survival and the other disease-free interval, which are related but nonidentical endpoints. The small sample size, heterogeneous treatment methods, and wide confidence intervals prevent firm conclusions about comparative disease control.
- MRI-based planning did not demonstrate lower severe gastrointestinal toxicity than CT-guided brachytherapy. Two retrospective studies involving 594 patients evaluated late grade ≥3 GI toxicity, with 345 receiving MRI-based or MRI-assisted treatment and 249 receiving CT guidance. The pooled risk ratio was 1.26 (95% CI 0.72–2.22; I²=0%), showing no statistically significant difference. A discrepancy in severe-event reporting within one included study was addressed through sensitivity analysis, which produced a similar estimate (RR 1.21, 95% CI 0.68–2.14).
- All pooled outcomes were graded as very-low-certainty evidence. The main limitations were retrospective treatment allocation, residual confounding, historical treatment-era effects, and small numbers of studies contributing to direct MRI-versus-CT analyses. MRI offers superior soft-tissue contrast for high-risk CTV delineation and adaptive planning, but this meta-analysis cannot establish whether these technical advantages independently improve survival, local control, or late toxicity compared with well-performed contemporary CT-guided adaptive brachytherapy.
CLINICAL TAKEAWAY
Modern image-guided adaptive brachytherapy is associated with better oncological outcomes than historical non-volumetric treatment for locally advanced cervical cancer. However, the available comparative evidence does not establish an incremental survival or toxicity advantage of MRI guidance over contemporary CT-guided brachytherapy, nor does it demonstrate equivalence. MRI remains valuable for anatomical delineation and treatment adaptation, while prospective comparative evidence is needed to quantify its independent clinical contribution.